Regulations for market access and reimbursement of medical devices vary across jurisdictions, complicating the development of innovative technologies for world-wide use; however, several converging regulatory principles are now emerging. Here we discuss approaches by which regulatory and related agencies can promote innovation and boost the effectiveness of regulatory processes to expedite patient access to innovative technologies, including renal replacement therapies.
Access options
Subscribe to Journal
Get full journal access for 1 year
$209.00
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1.
Luyckx, V. A., Tonelli, M. & Stanifer, J. W. Bull. World Health Organ. 96, 414–422 (2018).
- 2.
Nexight Group. Kidney Health Initiative https://www.asn-online.org/membership/BlastEmails/files/KHI_RRT_Roadmap1.0_FINAL_102318_web.pdf (2018).
- 3.
Global Medical Technology Alliance. GMTA http://www.globalmedicaltechnologyalliance.org/papers/GMTA%20Global%20Harmonization%20of%20Medical%20Technology%20Regulations.pdf (2018).
- 4.
World Health Organization. WHO Global Model Regulatory Framework for medical devices including in vitro diagnostic medical devices (WHO, 2017).
- 5.
IMDRF MDSAP Working Group. IMDRF http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-151002-mdra-audit-report.pdf (2015).
- 6.
Kristensen, F. B. et al. Value Health 22, 13–20 (2019).
- 7.
Wieringa, F. P. & Sheldon, M. Artificial Organs 44, 111–122 (2020).
- 8.
Benz, H. L. et al. Patient 12, 553–557 (2019).
- 9.
Mavris, M., Furia Helms, A. & Bere, N. Nat. Rev. Drug Discov. 18, 885–886 (2019).
Acknowledgements
The authors thank the Regulatory Affairs Professionals Society (RAPS) members A. Saaman (DebioTech), A. Purde (TÜV-SÜD) and K. Trautman (NSF International), as well as International Professional Society for Health Economics and Outcomes Research (ISPOR) members B. Gingles (Cook Medical) and T. Tesoro (ISPOR) for reviewing and providing input into this article. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.
Author information
Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
International Medical Device Regulators Forum (IMDRF): http://www.imdrf.org/
International Professional Society for Health Economics and Outcomes Research (ISPOR): https://www.ispor.org/
Kidney Health Initiative: https://khi.asn-online.org/
Regulatory Affairs Professionals Society (RAPS): https://www.raps.org/
Rights and permissions
About this article
Cite this article
Wieringa, F.P., Sheldon, M.I. & Hidalgo-Simon, A. Regulatory approaches to stimulate innovative renal replacement therapies. Nat Rev Nephrol 16, 546–547 (2020). https://doi.org/10.1038/s41581-020-0275-8
Published:
Issue Date:
Further reading
-
Frontiers in hemodialysis: Innovations and technological advances
Artificial Organs (2021)
-
Moving ahead on the Kidney Health Initiative innovation roadmap, a transatlantic progress update
Artificial Organs (2020)
-
The current and future landscape of dialysis
Nature Reviews Nephrology (2020)
